Asset
ENOBLITUZUMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02982941 | phase1 | completed | 2016-12-01 | 2019-05-22 | MacroGenics | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors |
| NCT04129320 | phase2_3 | withdrawn | 2019-10-01 | 2020-10-01 | MacroGenics | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck |
| NCT04634825 | phase2 | terminated | 2021-03-17 | 2022-07-29 | MacroGenics | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer |
| NCT01391143 | phase1 | completed | 2011-07-01 | 2019-04-18 | MacroGenics | Safety Study of MGA271 in Refractory Cancer |
| NCT01918930 | phase1 | terminated | 2013-07-01 | 2016-10-01 | MacroGenics | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 |
FDA applications (0)
This company has no applications containing this asset.